Alecensa Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Alectinib

Indications/Uses

1st line treatment of patients w/ anaplastic lymphoma kinase (ALK) +ve, locally advanced or metastatic NSCLC & in those who have progressed on or are intolerant to crizotinib. Monotherapy as adjuvant treatment following complete tumor resection for adult patients w/ ALK +ve NSCLC at high recurrence risk.

Dosage/Direction for Use

600 mg bd. Dose reduction schedule: 1st dose: 450 mg bd. 2nd dose: 300 mg bd. Locally advanced or metastatic NSCLC Duration of treatment: Until disease progression or unmanageable toxicity. Adjuvant treatment of resected NSCLC Duration of treatment: Until disease progression or unmanageable toxicity or for 2 yr. Severe hepatic impairment 450 mg bd.

Administration

Should be taken with food: Swallow whole, do not open/dissolve.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01ED03 - alectinib ; Belongs to the class of anaplastic lymphoma kinase (ALK) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Alecensa hard cap 150 mg

Packing/Price

1's

Alecensa

alectinib

Manufacturer:

Delpharm Milano S.r.l.